Disease activity-free rates at 1 and 2 years


REPORT FROM THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING, SAN DIEGO, CA, MARCH 16-23, 2013 – An emerging metric in MS research is the proportion of patients who are disease-activity free (DAF), defined as no relapses, no MRI activity (T2 or Gd+ T1 lesions) and no sustained EDSS progression. One of the first uses was an analysis of the AFFIRM dataset, which reported a two-year DAF rate of 37% with natalizumab versus 7% with placebo (Havrdova et al. Lancet Neurol 2009;8:254-260).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page